$LGND Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in LIGAND PHARMACEUTICALS INC. Get notifications about new insider transactions in LIGAND PHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 08 2021 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 08 2021 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Grant | A | 0.00 | 630 | 0 | 25,061 | 24.4 K to 25.1 K (+2.58 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 630 | 0 | 68,664 | 68 K to 68.7 K (+0.93 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 630 | 0 | 68,664 | 68 K to 68.7 K (+0.93 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Grant | A | 0.00 | 630 | 0 | 2,892 | 2.3 K to 2.9 K (+27.85 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Grant | A | 0.00 | 630 | 0 | 3,702 | 3.1 K to 3.7 K (+20.51 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Grant | A | 0.00 | 630 | 0 | 2,892 | 2.3 K to 2.9 K (+27.85 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Grant | A | 0.00 | 630 | 0 | 3,702 | 3.1 K to 3.7 K (+20.51 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Grant | A | 0.00 | 630 | 0 | 28,820 | 28.2 K to 28.8 K (+2.23 %) |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Option Exercise | A | 115.39 | 3,269 | 377,210 | 3,269 | |
| Jun 07 2021 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Grant | A | 0.00 | 630 | 0 | 28,820 | 28.2 K to 28.8 K (+2.23 %) |
| May 13 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | M | 10.12 | 4,835 | 48,930 | 0 | |
| May 13 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Payment of Exercise | F | 128.56 | 391 | 50,267 | 34,152 | 34.5 K to 34.2 K (-1.13 %) |
| May 13 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | M | 10.12 | 4,835 | 48,930 | 34,543 | 29.7 K to 34.5 K (+16.28 %) |
| Feb 23 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | M | 10.12 | 2,500 | 25,300 | 4,835 | |
| Feb 23 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | M | 10.12 | 2,500 | 25,300 | 29,708 | 27.2 K to 29.7 K (+9.19 %) |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 195.91 | 2,474 | 484,681 | 0 | |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 195.91 | 2,474 | 484,681 | 50,152 | 47.7 K to 50.2 K (+5.19 %) |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Sell | S | 213.14 | 5,083 | 1,083,410 | 47,678 | 52.8 K to 47.7 K (-9.63 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 54,666 | 791,017 | 14,334 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 10.05 | 60,000 | 603,000 | 0 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 203.03 | 2,970 | 602,999 | 343,060 | 346 K to 343.1 K (-0.86 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 10.05 | 60,000 | 603,000 | 346,030 | 286 K to 346 K (+20.98 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 203.40 | 54,666 | 11,119,239 | 286,030 | 340.7 K to 286 K (-16.05 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 54,666 | 791,017 | 340,696 | 286 K to 340.7 K (+19.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | A | 177.50 | 6,955 | 1,234,513 | 6,955 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Sell | S | 178.50 | 18,097 | 3,230,376 | 28,906 | 47 K to 28.9 K (-38.50 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 3,491 | 0 | 47,003 | 43.5 K to 47 K (+8.02 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 177.50 | 13,136 | 2,331,640 | 13,136 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 74.42 | 1,000 | 74,420 | 63,210 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 44,547 | 976,470 | 20,000 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 176.86 | 44,547 | 7,878,582 | 168,198 | 212.7 K to 168.2 K (-20.94 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 44,547 | 976,470 | 212,745 | 168.2 K to 212.7 K (+26.48 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 74.42 | 1,000 | 74,420 | 168,198 | 167.2 K to 168.2 K (+0.60 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 6,595 | 0 | 167,198 | 160.6 K to 167.2 K (+4.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 177.50 | 25,113 | 4,457,558 | 25,113 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 12,608 | 0 | 286,030 | 273.4 K to 286 K (+4.61 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 177.50 | 11,591 | 2,057,403 | 11,591 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 10,819 | 0 | 41,752 | 30.9 K to 41.8 K (+34.98 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.92 | 30,000 | 657,600 | 65,616 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 40,000 | 578,800 | 69,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 50,000 | 723,500 | 109,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.92 | 30,000 | 657,600 | 273,422 | 243.4 K to 273.4 K (+12.32 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 182.00 | 40,000 | 7,280,000 | 243,422 | 283.4 K to 243.4 K (-14.11 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 40,000 | 578,800 | 283,422 | 243.4 K to 283.4 K (+16.43 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 4,596 | 717,022 | 243,422 | 248 K to 243.4 K (-1.85 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,607 | 0 | 248,018 | 238.4 K to 248 K (+4.03 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 2,845 | 443,848 | 238,411 | 241.3 K to 238.4 K (-1.18 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 5,946 | 0 | 241,256 | 235.3 K to 241.3 K (+2.53 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 159.00 | 50,000 | 7,950,000 | 235,310 | 285.3 K to 235.3 K (-17.52 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 50,000 | 723,500 | 285,310 | 235.3 K to 285.3 K (+21.25 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 156.01 | 2,272 | 354,455 | 160,603 | 162.9 K to 160.6 K (-1.39 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 5,604 | 0 | 162,875 | 157.3 K to 162.9 K (+3.56 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 156.01 | 1,053 | 164,279 | 157,271 | 158.3 K to 157.3 K (-0.67 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 2,911 | 0 | 158,324 | 155.4 K to 158.3 K (+1.87 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 1,440 | 224,654 | 30,933 | 32.4 K to 30.9 K (-4.45 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 4,803 | 0 | 32,373 | 27.6 K to 32.4 K (+17.42 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 671 | 104,683 | 27,570 | 28.2 K to 27.6 K (-2.38 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,305 | 0 | 28,241 | 25.9 K to 28.2 K (+8.89 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 156.01 | 830 | 129,488 | 43,512 | 44.3 K to 43.5 K (-1.87 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 2,401 | 0 | 44,342 | 41.9 K to 44.3 K (+5.72 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 156.10 | 509 | 79,455 | 41,941 | 42.5 K to 41.9 K (-1.20 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 1,335 | 0 | 42,450 | 41.1 K to 42.5 K (+3.25 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 113.50 | 2,456 | 278,756 | 0 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 113.50 | 2,456 | 278,756 | 52,761 | 50.3 K to 52.8 K (+4.88 %) |
| Jan 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | J | 84.53 | 223 | 18,851 | 235,310 | 235.1 K to 235.3 K (+0.09 %) |
| Nov 04 2020 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Buy | P | 82.52 | 1,000 | 82,520 | 28,190 | 27.2 K to 28.2 K (+3.68 %) |
| Aug 27 2020 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.11 | 94,488 | 766,109 | 5,819,383 | 5.9 M to 5.8 M (-1.60 %) |
| Aug 27 2020 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.11 | 94,488 | 766,109 | 5,819,383 | 5.9 M to 5.8 M (-1.60 %) |
| Aug 27 2020 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.02 | 70,000 | 561,575 | 5,968,083 | 6 M to 6 M (-1.16 %) |
| Aug 27 2020 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.02 | 70,000 | 561,575 | 5,968,083 | 6 M to 6 M (-1.16 %) |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 74.42 | 790 | 58,792 | 64,210 | |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 78 | 1,710 | 64,547 | |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 14.47 | 7,225 | 104,546 | 0 | |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 110.89 | 78 | 8,649 | 155,413 | 155.5 K to 155.4 K (-0.05 %) |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 78 | 1,710 | 155,491 | 155.4 K to 155.5 K (+0.05 %) |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 112.88 | 7,225 | 815,541 | 155,413 | 162.6 K to 155.4 K (-4.44 %) |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 14.47 | 7,225 | 104,546 | 162,638 | 155.4 K to 162.6 K (+4.65 %) |
| Aug 25 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 74.42 | 790 | 58,792 | 155,413 | 154.6 K to 155.4 K (+0.51 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 85.79 | 1,165 | 99,945 | 54,226 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 74.42 | 1,373 | 102,179 | 93,627 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 56.26 | 1,777 | 99,974 | 54,421 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 74.42 | 1,373 | 102,179 | 204,571 | 203.2 K to 204.6 K (+0.68 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 56.26 | 1,777 | 99,974 | 203,198 | 201.4 K to 203.2 K (+0.88 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 85.79 | 1,165 | 99,945 | 201,421 | 200.3 K to 201.4 K (+0.58 %) |
| Jul 01 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | J | 89.03 | 238 | 21,189 | 41,115 | 40.9 K to 41.1 K (+0.58 %) |
| Jul 01 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | J | 89.03 | 238 | 21,189 | 25,936 | 25.7 K to 25.9 K (+0.93 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Grant | A | 0.00 | 831 | 0 | 24,431 | 23.6 K to 24.4 K (+3.52 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 831 | 0 | 68,034 | 67.2 K to 68 K (+1.24 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Boyce Sarah | Director | Grant | A | 0.00 | 831 | 0 | 2,262 | 1.4 K to 2.3 K (+58.07 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 831 | 0 | 50,305 | 49.5 K to 50.3 K (+1.68 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Gray Nancy Ryan | Director | Grant | A | 0.00 | 831 | 0 | 3,072 | 2.2 K to 3.1 K (+37.08 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Grant | A | 0.00 | 831 | 0 | 27,208 | 26.4 K to 27.2 K (+3.15 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Grant | A | 0.00 | 831 | 0 | 24,768 | 23.9 K to 24.8 K (+3.47 %) |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Option Exercise | A | 117.58 | 2,468 | 290,187 | 2,468 | |
| Jun 12 2020 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Grant | A | 0.00 | 831 | 0 | 27,190 | 26.4 K to 27.2 K (+3.15 %) |
| Jun 05 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Sell | S | 118.59 | 11,146 | 1,321,775 | 40,877 | 52 K to 40.9 K (-21.43 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 435 | 52,574 | 15,303 | 15.7 K to 15.3 K (-2.76 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 377 | 45,564 | 15,738 | 16.1 K to 15.7 K (-2.34 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 354 | 42,784 | 16,115 | 16.5 K to 16.1 K (-2.15 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 120.86 | 642 | 77,592 | 122,727 | 123.4 K to 122.7 K (-0.52 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 120.86 | 1,246 | 150,592 | 123,369 | 124.6 K to 123.4 K (-1.00 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 120.86 | 938 | 113,367 | 124,615 | 125.6 K to 124.6 K (-0.75 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,310 | 158,327 | 133,982 | 135.3 K to 134 K (-0.97 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,689 | 204,133 | 135,292 | 137 K to 135.3 K (-1.23 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,918 | 231,809 | 136,981 | 138.9 K to 137 K (-1.38 %) |
| Mar 13 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 2,000 | 43,840 | 64,625 | |
| Mar 13 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 2,000 | 43,840 | 157,449 | 155.4 K to 157.4 K (+1.29 %) |
| Feb 27 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 1,706 | 37,396 | 66,625 | |
| Feb 27 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 14.47 | 7,225 | 104,546 | 7,225 | |
| Feb 27 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 1,706 | 37,396 | 155,449 | 153.7 K to 155.4 K (+1.11 %) |
| Feb 27 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 110.00 | 7,225 | 794,750 | 153,743 | 161 K to 153.7 K (-4.49 %) |
| Feb 27 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 14.47 | 7,225 | 104,546 | 160,968 | 153.7 K to 161 K (+4.70 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 9.96 | 48,125 | 479,325 | 0 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 95.68 | 60,886 | 5,825,572 | 60,886 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 2,117 | 205,836 | 205,173 | 207.3 K to 205.2 K (-1.02 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 1,310 | 127,371 | 207,290 | 208.6 K to 207.3 K (-0.63 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 1,689 | 164,221 | 208,600 | 210.3 K to 208.6 K (-0.80 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 13,559 | 0 | 210,289 | 196.7 K to 210.3 K (+6.89 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 95.68 | 5,009 | 479,261 | 196,730 | 201.7 K to 196.7 K (-2.48 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 9.96 | 48,125 | 479,325 | 201,739 | 153.6 K to 201.7 K (+31.33 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 95.68 | 33,210 | 3,177,533 | 33,210 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 496 | 10,872 | 68,331 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 14.47 | 7,225 | 104,546 | 14,450 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 97.23 | 1,170 | 113,759 | 153,743 | 154.9 K to 153.7 K (-0.76 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 97.23 | 447 | 43,462 | 154,913 | 155.4 K to 154.9 K (-0.29 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 97.23 | 869 | 84,493 | 155,360 | 156.2 K to 155.4 K (-0.56 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 95.84 | 7,225 | 692,467 | 156,229 | 163.5 K to 156.2 K (-4.42 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 14.47 | 7,225 | 104,546 | 163,454 | 156.2 K to 163.5 K (+4.62 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 7,396 | 0 | 156,229 | 148.8 K to 156.2 K (+4.97 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 496 | 10,872 | 148,833 | 148.3 K to 148.8 K (+0.33 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | A | 95.68 | 17,220 | 1,647,610 | 17,220 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 97.23 | 367 | 35,683 | 52,023 | 52.4 K to 52 K (-0.70 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 97.23 | 207 | 20,127 | 52,390 | 52.6 K to 52.4 K (-0.39 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 97.23 | 307 | 29,850 | 52,597 | 52.9 K to 52.6 K (-0.58 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 3,835 | 0 | 52,904 | 49.1 K to 52.9 K (+7.82 %) |